Whitehawk Therapeutics (WHWK) officer sells 118,849 shares for RSU tax withholding

Q: At what prices were the WHWK shares sold by Bryan Ball?

Bryan Ball’s reported sales were executed at $3.46 and $3.64 per share. The 26,389-share sale on April 13 cleared at $3.46, while the 92,460-share sale on April 14 cleared at $3.64 in broker-assisted transactions.

Q: Why did Bryan Ball sell Whitehawk Therapeutics (WHWK) shares?

The sales were executed to satisfy tax withholding obligations from the vesting of restricted stock units. A footnote specifies these were broker-assisted sales for tax purposes, indicating they were compensation-related rather than discretionary decisions about Whitehawk Therapeutics’ stock.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Whitehawk Therapeutics officer Bryan Ball reported broker-assisted sales of company common stock to cover taxes on vested restricted stock units. On April 13, he sold 26,389 shares at $3.46 per share, and on April 14 he sold 92,460 shares at $3.64 per share. A footnote clarifies these transactions were solely to satisfy tax withholding obligations related to RSU vesting, making them compensation-driven rather than discretionary portfolio sales. After these transactions, Ball directly held 397,106 shares of Whitehawk Therapeutics common stock.

Insider Trade Summary

Net Seller: 118,849 shares ($427,860)

Net Sell 2 txns

Insider BALL BRYAN

Role See remarks

Sold 118,849 shs ($428K)

Type	Security	Shares	Price	Value
Sale	Common Stock	92,460	$3.64	$337K
Sale	Common Stock	26,389	$3.46	$91K

Holdings After Transaction: Common Stock — 397,106 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Total shares sold: 118,849 shares April 13 sale: 26,389 shares at $3.46 April 14 sale: 92,460 shares at $3.64 +1 more

4 metrics

Total shares sold 118,849 shares Broker-assisted sales on April 13–14, 2026

April 13 sale 26,389 shares at $3.46 Open-market sale to cover RSU tax withholding

April 14 sale 92,460 shares at $3.64 Open-market sale to cover RSU tax withholding

Shares held after transactions 397,106 shares Direct ownership following April 14, 2026 sale

Key Terms

restricted stock units, broker-assisted sale, tax withholding obligations, Form 4

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

broker-assisted sale financial

"Represents a broker-assisted sale to satisfy the Reporting Person's tax"

tax withholding obligations financial

"sale to satisfy the Reporting Person's tax withholding obligations"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 07:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BALL BRYAN

(Last)

(First)

(Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN

NEW JERSEY

07960

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/13/2026		S⁽¹⁾		26,389	D	$3.46	489,566	D
Common Stock	04/14/2026		S⁽¹⁾		92,460	D	$3.64	397,106	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

Chief Technical Operations Officer and SVP, Manufacturing Operations

	/s/ Stephen Rodin, as Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did WHWK officer Bryan Ball report?

Bryan Ball reported two broker-assisted sales of Whitehawk Therapeutics common stock totaling 118,849 shares. These transactions occurred on April 13 and April 14 and were carried out to cover tax withholding obligations tied to vested restricted stock units.

At what prices were the WHWK shares sold by Bryan Ball?

Bryan Ball’s reported sales were executed at $3.46 and $3.64 per share. The 26,389-share sale on April 13 cleared at $3.46, while the 92,460-share sale on April 14 cleared at $3.64 in broker-assisted transactions.

Why did Bryan Ball sell Whitehawk Therapeutics (WHWK) shares?

The sales were executed to satisfy tax withholding obligations from the vesting of restricted stock units. A footnote specifies these were broker-assisted sales for tax purposes, indicating they were compensation-related rather than discretionary decisions about Whitehawk Therapeutics’ stock.

How many WHWK shares does Bryan Ball hold after these transactions?

Following the reported broker-assisted sales, Bryan Ball directly holds 397,106 shares of Whitehawk Therapeutics common stock. This post-transaction balance is disclosed in the Form 4 and reflects his remaining direct ownership after covering tax obligations on vested RSUs.

How many Whitehawk Therapeutics (WHWK) shares did Bryan Ball sell in total?

Across the two reported transactions, Bryan Ball sold a total of 118,849 shares of Whitehawk Therapeutics common stock. This figure combines 26,389 shares sold on April 13 and 92,460 shares sold on April 14 to cover RSU-related tax withholdings.